TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of Grade 2 to 5 RP
Endpoint domain: Adverse events/effects
Primary endpoint: Number of systemic corticosteroid bursts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in asthma control according to physician's assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in asthma control according to patient's assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Periodontal probing depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty in chewing and kissing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ΔDAS28 ⩾ 1.2 and/or DAS28 low disease activity achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 low disease activity achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent thrombosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Activation/PAM scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADHD symptom response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest systolic blood pressure after spinal blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of ephedrine to treat hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual recurrent infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: incident C trachomatis infection
Endpoint domain: Adverse events/effects
Primary endpoint: Lowest SaO₂ value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sleep structure improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Motor onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma potassium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Electrolyte outcomes
Primary endpoint: mean defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety measures
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular cavity enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prediction of NEC outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous preterm birth (PTB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: NDS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse events related to anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of bacteremia, bronchitis, and ventilator‐associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: painful symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erectile potency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of addiction consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oxyhemoglobin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of psychotherapy vs bupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality of brain CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of curcumin sulfate and curcumin glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum level of free curcumin (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total curcumin absorbed (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioimpedance phase angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of mucositis severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to swallow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mouth pain and oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of ventilator dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: need for reintubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: length of stay in neonatal intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Need for tracheotomy
Endpoint domain: Adverse events/effects
Primary endpoint: upregulation of CD154 on platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of soluble CD154
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: numbers of prothrombotic platelet‐monocyte aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: retention of erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine levels in drainage fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endothelial cell proliferation and migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiogenic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean RAIU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported instrumental activities of daily living (IADLs)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Preference for MELT formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bedwetting episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of pneumothorax progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dynamic posturography overall score (DMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median direct cost of complete denture treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pirani score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of relapse surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with abduction splint treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk perception improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Capacity to discern safer options
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in ALT and AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained response after antiviral therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ventilation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: EBMIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission of T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: remission of HT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: remission of DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of Lactobacillus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Onset of therapeutic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dizziness as an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of having a newborn with macrosomia
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of having acute and elective caesarean delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Infiltration of tumor-infiltrating lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tensile bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Frequency rate of late postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total costs for treatment of complications
Endpoint domain: Resource use
Primary endpoint: Reduction in CP (Cerebral Palsy)
Endpoint domain: Mortality/survival
Primary endpoint: CD4 proliferative responses to KLH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8 proliferative responses to KLH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 proliferative responses to HIV‐1 Gag
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 proliferative responses to HIV‐1 Nef
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants reaching physical activity target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐caloric nystagmus slow‐phase velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular head displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular head acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear head acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial serum c-erbB-2 levels correlation with clinical course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking score
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of tolpersione in acute nonspecific back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal cut-off of P2Y12 reaction units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ADHD and oppositional-defiant symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual analogue pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in systemic vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Central line insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of vertigo
Endpoint domain: Adverse events/effects
Primary endpoint: amelioration of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: amelioration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Magnitude of perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of dyspepsia
Endpoint domain: Adverse events/effects
Primary endpoint: Show rates at follow-up appointments
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: ulcer recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ulcer-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neural noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: psychosis-like positive and disorganization symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from non-reactive to reactive NST results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain of three or more lines in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of affective dysregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impulsive aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WKT increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P(a-ET)CO2 difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LDL-apolipoprotein B reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability profile of regorafenib eye drops
Endpoint domain: Adverse events/effects
Primary endpoint: mean absorbed doses in the tumour region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaesthesia costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of non responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 at the anaerobic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of eating disorder pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oral dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS (Numeric Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of BAY 63-9044
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-dependent changes of DIAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentrations of BAY 63-9044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean performance score in test-2
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean time required to complete test-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score during active and passive functional exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced risk of stroke, myocardial infarction or death
Endpoint domain: Mortality/survival
Primary endpoint: Graft vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time duration of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dyskinesia
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy half-time of levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of protocol-related discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients completing 2 years of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of dose reduction due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of exposure to blood/body fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of underreporting of blood/body fluid exposure incidents
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Instrumental vaginal birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Episiotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: QTcF changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VO2max decline from normoxia to mild hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical complications requiring catheter removal
Endpoint domain: Adverse events/effects
Primary endpoint: Daily cost for maintenance
Endpoint domain: Resource use
Primary endpoint: Frequency of catheter malfunction
Endpoint domain: Adverse events/effects
Primary endpoint: silent brain infarction detected by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical response with respect to dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response with respect to nonmenstrual pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption of targeted practices
Endpoint domain: Delivery of care
Primary endpoint: Plasma folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wall motion score index (WMSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SEBR (Saccadic Eye Blink Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of incomplete blinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum sL-selectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum exposure of tramadol (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of tramadol exposure (AUC(0‐48))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breakthrough rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in corrected QT interval (QTc) by >20ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in FV purchasing and consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and effectiveness of ABSORB BVS compared to XIENCE EES
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV RNA < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of epicatechin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of catechin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet function (ADP‐induced and collagen‐induced aggregation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot and ankle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with footwear and orthoses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Latency between stimuli and response in arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean difference in FEV1 (LAR 3‐10 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coercion during sexual initiation
Endpoint domain: Adverse events/effects
Primary endpoint: Interleukin-6 serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spontaneous release of hydrogen peroxide by neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duration of arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Utility values
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in positive psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal FEV1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrent rate after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Middle ear cavity effusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bone mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in right-frontal, 9-10 Hz, conflict-specific power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes